These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Di Pauli F; Mader S; Rostasy K; Schanda K; Bajer-Kornek B; Ehling R; Deisenhammer F; Reindl M; Berger T Clin Immunol; 2011 Mar; 138(3):247-54. PubMed ID: 21169067 [TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Hennes EM; Baumann M; Schanda K; Anlar B; Bajer-Kornek B; Blaschek A; Brantner-Inthaler S; Diepold K; Eisenkölbl A; Gotwald T; Kuchukhidze G; Gruber-Sedlmayr U; Häusler M; Höftberger R; Karenfort M; Klein A; Koch J; Kraus V; Lechner C; Leiz S; Leypoldt F; Mader S; Marquard K; Poggenburg I; Pohl D; Pritsch M; Raucherzauner M; Schimmel M; Thiels C; Tibussek D; Vieker S; Zeches C; Berger T; Reindl M; Rostásy K; Neurology; 2017 Aug; 89(9):900-908. PubMed ID: 28768844 [TBL] [Abstract][Full Text] [Related]
29. Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity. Xu Y; Zhang Y; Liu CY; Peng B; Wang JM; Zhang XJ; Li HF; Cui LY Chin Med J (Engl); 2012 Sep; 125(18):3207-10. PubMed ID: 22964310 [TBL] [Abstract][Full Text] [Related]
30. Viability of autoantibody-targets: how to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. Mayer MC; Hohlfeld R; Meinl E J Neurol Sci; 2012 Aug; 319(1-2):2-7. PubMed ID: 22647585 [TBL] [Abstract][Full Text] [Related]
31. [The effect of azathioprine treatment on IgG subclasses in multiple sclerosis]. Losy J; Michałowska-Wender G; Wender M Neurol Neurochir Pol; 1993; 27(1):39-44. PubMed ID: 8502358 [TBL] [Abstract][Full Text] [Related]
32. Detection of anti-Nogo receptor autoantibody in the serum of multiple sclerosis and controls. Onoue H; Satoh JI; Ogawa M; Tabunoki H; Yamamura T Acta Neurol Scand; 2007 Mar; 115(3):153-60. PubMed ID: 17295709 [TBL] [Abstract][Full Text] [Related]
34. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy? Lee DH; Linker RA Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461 [TBL] [Abstract][Full Text] [Related]
35. MOG Antibodies in Pediatric Neurology. Huppke P Neuropediatrics; 2018 Feb; 49(1):1-2. PubMed ID: 28915516 [No Abstract] [Full Text] [Related]
36. Failure of alemtuzumab therapy to control MOG encephalomyelitis. Wildemann B; Jarius S; Schwarz A; Diem R; Viehöver A; Hähnel S; Reindl M; Korporal-Kuhnke M Neurology; 2017 Jul; 89(2):207-209. PubMed ID: 28600462 [No Abstract] [Full Text] [Related]
37. Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity. Amin M; Mays M; Polston D; Flanagan EP; Prayson R; Kunchok A J Neuroimmunol; 2021 Dec; 361():577743. PubMed ID: 34695769 [TBL] [Abstract][Full Text] [Related]